US broker round-up
Top US stock recommendations of the day: ABBOTT LABORATORIES: Goldman Sachs upgrades to BUY from neutral.
Fri May 17, 2013
The Motley Fool
Abbott Laboratories Stock Checkup for May
Most of us go to the doctor for a checkup once per year. Many of us visit our dentists twice per year.
Mon May 13, 2013
REVA Appoints Managing Director International
REVA Medical, Inc. is pleased to announce that Michel Vanbrabant has been appointed Managing Director International for the Company.
Fri May 10, 2013
BEAM Inc (BEAM), Abbott Laboratories (ABT): Some Investing Lessons To Pay Attention To
If I could send a message back in time to my younger self, I would only need to use four words, "Keep it simple, Stupid!" This is great advice for life in general, but especially good advice when investing one's own money.
Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million
This is the first Humira lawsuit filed against Abbott to go to trial. "We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney , Delores began experiencing chest pain and fevers.
Thu May 09, 2013
Gleacher & Company (GLCH) Releases Quarterly Earnings Results
Gleacher & Company announced its earnings results on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.12, Analyst Ratings Network reports.
Local Companies Make Fortune 500
Area companies have made the Fortune 500 list for 2013, including Abbott Laboratories and CDW.
Wed May 08, 2013
Abbott Laboratories to Present at Healthcare Conference
A live audio webcast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com . An archived edition of the presentation will be available later that day.
Cantor Fitzgerald & Co. Strengthens Its Credit Fixed Income Team
These individuals will focus on High Yield and Investment Grade Sales and Trading, and building out the firm's credit platform.
Tue May 07, 2013
SUMMIT-Drug industry CEOs plotting more carve-outs
A new generation of drug industry chief executives is stepping up plans to restructure their businesses by divesting slower-growing and maturing operations, opening up new opportunities for deal-makers. Bankers speaking at the Reuters Health Summit said the success of transactions such as Pfizer Inc's divestitures of noncore assets and Abbott ... (more)
Fri May 03, 2013
Nestle and Mead Johnson Nutrition dismiss call to remove GMOs from US infant formula
NestlA© USA and Mead Johnson Nutrition have dismissed calls to remove genetically-modified organisms ingredients from their infant formula products in the US - citing the approved use of GMOs by several national and global regulatory bodies.
Thu May 02, 2013
Abbott Laboratories Given "Market Perform" Rating at Sanford C. Bernstein
's stock had its "market perform" rating restated by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports.
Tue Apr 30, 2013
Abbott Laboratories shareholders reject proposal to remove GMOs from infant formula
An Abbott Laboratories shareholder proposal to remove genetically-modified organisms from its natural products - including its Similac infant formula range - has been rejected, the Illinois-based company has revealed.
The Motley Fool
Abbott Laboratories Stock Is Half What It Used to Be
The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... Abbott Laboratories stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie .
Sat Apr 27, 2013
AbbVie 1Q earnings top analyst estimates AbbVie Inc. topped Wall...
AbbVie Inc. topped Wall Street expectations in its first three months as a standalone company and shares bounced within a penny of a record high Friday.
Fri Apr 26, 2013
AbbVie Earnings Beats Analysts' Estimates in First Quarter Since Split-Up
AbbVie Inc. reported earnings that beat analysts' estimates on higher sales of the rheumatoid arthritis treatment Humira in the first quarter since the drugmaker was split from parent Abbott Laboratories.
Crain's Chicago Busines
AbbVie beats estimates as Humira sales jump
AbbVie Inc. reported slightly better than expected quarterly results today, fueled by surging sales of its Humira treatment for rheumatoid arthritis.
Thu Apr 25, 2013
Investors ask maker of Similac baby formula to remove GMOs
Abbott Laboratories, one of the world's top ten pharmaceutical and nutritional product companies, is using genetically modified corn and soy in its popular Similac infant formula and investors don't like it.
Tue Apr 23, 2013
Pressure Mounts to Remove GMOs From Infant Formula
April 23 - Shareholders of Abbott Laboratories will vote on whether the manufacturer of Similac, a leading brand of infant formula, should adopt a policy of sourcing ingredients that have not been genetically engineered.
Mon Apr 22, 2013
The Motley Fool
Yawn Your Way to Retirement With Abbott Laboratories Stock
Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today.